Changes in adenosine 5′-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 12, 2008, Pages 4969-4973

  Kola, Blerina ^a   Christ Crain, Mirjam ^a   Lolli, Francesca ^a   Arnaldi, Giorgio ^b   Giacchetti, Gilberta ^b   Boscaro, Marco ^b   Grossman, Ashley B ^a   Korbonits, Márta ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP);

ABDOMINAL SURGERY; ADRENAL INCIDENTALOMA; ADULT; APPETITE; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; ENZYME REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; INTRAABDOMINAL FAT; LIPID METABOLISM; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 57349092160     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1297     Document Type: Article

References (24)

1. Kola B, Grossman AB 2008 Dynamic testing in Cushing's syndrome. Pituitary 11:155-162
2. Gudbjornsson B, Juliusson UI, Gudjonsson FV 2002 Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61:32-36
3. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C 2000 Use of oral corticosteroids in the United Kingdom. QJM 93:105-111
4. Walsh LJ, Wong CA, Pringle M, Tattersfield AE 1996 Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313:344-346
5. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M 2003 Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593-5602
6. Mayo-Smith W, Hayes CW, Biller BM, Klibanski A, Rosenthal H, Rosenthal DI 1989 Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology 170:515-518
7. Kahn BB, Alquier T, Carling D, Hardie DG 2005 AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15-25
8. Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, Feltrin D, Igreja SC, Ajodha S, Harvey-White J, Kunos G, Muller B, Pralong F, Aubert G, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M 2008 AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 22:1672-1683
9. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E 1996 Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 271:E317-E325
10. Steinberg GR, Smith AC, Van Denderen BJ, Chen Z, Murthy S, Campbell DJ, Heigenhauser GJ, Dyck DJ, Kemp BE 2004 AMP-activated protein kinase is not down-regulated in human skeletal muscle of obese females. J Clin Endocrinol Metab 89:4575-4580
11. Hojlund K, Mustard KJ, Staehr P, Hardie DG, Beck-Nielsen H, Richter EA, Wojtaszewski JF 2004 AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes. Am J Physiol Endocrinol Metab 286:E239-E244
12. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM 2006 Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 55:2277-2285
13. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, Korbonits M 2005 Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280:25196-25201
14. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG 2003 Complexes between the LKB1 tumor suppressor, STRAD α/β and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2:28
15. Terzolo M, Reimondo G, Bovio S, Angeli A 2004 Subclinical Cushing's syndrome. Pituitary 7:217-223
16. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A 2000 A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637-644
17. Barzon L, Fallo F, Sonino N, Boscaro M 2002 Development of overt Cushing's syndrome in patients with adrenal incidentaloma. Eur J Endocrinol 146:61-66
18. Bujalska IJ, Kumar S, Stewart PM 1997 Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349:1210-1213
19. Seckl JR, Walker BR 2004 11β-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab 15:418-424
20. Daval M, Foufelle F, Ferre P 2006 Functions of AMP-activated protein kinase in adipose tissue. J Physiol 574:55-62
21. Wang Y, Jones Voy B, Urs S, Kim S, Soltani-Bejnood M, Quigley N, Heo YR, Standridge M, Andersen B, Dhar M, Joshi R, Wortman P, Taylor JW, Chun J, Leuze M, Claycombe K, Saxton AM, Moustaid-Moussa N 2004 The human fatty acid synthase gene and de novo lipogenesis are coordinately regulated in human adipose tissue. J Nutr 134:1032-1038
22. Vander Kooi BT, Onuma H, Oeser JK, Svitek CA, Allen SR, Vander Kooi CW, Chazin WJ, O'Brien RM 2005 The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol 19:3001-3022
23. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC 2005 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646
24. Clark AR 2007 Anti-inflammatory functions of glucocorticoid- induced genes. Mol Cell Endocrinol 275:79-97